BMS Reports Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Previously Treated Advanced Hepatocellular Carcinoma

 BMS Reports Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Previously Treated Advanced Hepatocellular Carcinoma

BMS Reports Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Previously Treated Advanced Hepatocellular Carcinoma

Shots:

  • The US FDA has accepted sBLA and granted BT designation for the dual regimen to treat patients with advanced HCC prior treated with sorafenib. The sBLA ha also received PR with the PDUFA date as Mar 10, 2020
  • The sBLA is based on P-I/II CheckMate -040 study assessing Opdivo or Opdivo + Yervoy s in patients with advanced HCC with and without chronic viral hepatitis who are naïve, intolerant to or prior treated with sorafenib therapy
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response, being evaluated in multiple clinical studies across all phases including P-III for multiple tumor

Click here to­ read full press release/ article | Ref: BMS | Image: Yahoo

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post